Medica Scientia Innovation Research (MedSIR)
Industry / private company
Location:
Barcelona,
Spain (ES)
ROR: https://ror.org/00t6sz979
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial (2025)
Cardoso F, O’Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, et al.
Journal article
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024)
Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al.
Journal article